Global Nanomaterials in Personalized Medicine Market Size study & Forecast, by Product Type (Proteins, Monoclonal Antibodies, Nanocrystals, Liposomes, Gold Nanoparticles, Quantum Dots) and Regional Analysis, 2023-2030

Global Nanomaterials in Personalized Medicine Market Size study & Forecast, by Product Type (Proteins, Monoclonal Antibodies, Nanocrystals, Liposomes, Gold Nanoparticles, Quantum Dots) and Regional Analysis, 2023-2030

Global Nanomaterials in Personalized Medicine Market is valued approximately USD 311.50 billion in 2022 and is anticipated to grow with a growth rate of more than 11.3% over the forecast period 2023-2030. Nanomaterials in Personalized Medicine refer to materials at the nanoscale that are engineered and designed for applications in the field of personalized healthcare. Personalized medicine aims to tailor medical treatment to the individual characteristics of each patient, considering factors such as genetics, environment and lifestyle. Nanomaterials play a crucial role in this context by offering unique properties and capabilities. Use of Nanomaterials in Personalized Medicine market is expanding because of factors such as growing prevalence of cancer and increasing number of diabetes cases. Nanomaterials are employed in theragnostic platforms that combine diagnostic and therapeutic functionalities. These platforms enable simultaneous imaging and treatment, allowing healthcare providers to monitor treatment responses and adjust therapies based on individual patient needs. As a result, the demand of Nanomaterials in Personalized Medicine has progressively increased in the international market during the forecast period 2023-2030.

Nanomaterials can be engineered to deliver anticancer drugs directly to tumor sites, increasing drug concentration at the target and minimizing damage to healthy tissues. The heterogeneity of cancer requires personalized approaches, and nanocarriers can be tailored to specific cancer types or even individual patient profiles. According to Global Cancer Observatory, the number of Brain, nervous system cancer cases across the world accounts 308 thousand cases in 2020 and is projected to reach up to 372 thousand cases by the year 2030. Furthermore, as per World Health Organization, in 2020, it was estimated that nearly 19.3 million new cases of cancer were recorded globally, which is projected to rise and is likely to reach 30.2 million new cases by 2040. Another important factor driving the Nanomaterials in Personalized Medicine market is increasing number of diabetes cases. Nanomaterial-based biosensors can be employed for more sensitive and accurate monitoring of blood glucose levels in diabetic patients. These biosensors can offer real-time data, allowing for better management of diabetes and customization of treatment plans based on individual glucose variations. In addition, as per American Diabetes Association, in 2021, 38.4 million Americans, or 11.6% of the total population, had diabetes 2 million Americans with type 1 diabetes, including around 304,000 children and adolescents. Moreover, growing cases of hypercholesterolemia and technological advancements associated with nanomaterials in personalized medicine is anticipated to create a lucrative growth opportunity for the market over the forecast period. However, high development cost of personalized medicine and government regulations regarding formulation of personalized medicine is going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Nanomaterials in Personalized Medicine Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the growing research and development in personalized medicine in the region. Advances in personalized medicine contribute to the identification of specific biomarkers associated with diseases. Nanomaterials can be engineered to detect and target these biomarkers, enabling early diagnosis and personalized treatment strategies. The region’s dominant performance is anticipated to propel the overall demand of Nanomaterials in Personalized Medicine. Furthermore, Asia Pacific is expected to grow as a fastest growing region during the forecast period, owing to factors such as growing healthcare spending in the region. Increased funding allows healthcare institutions to invest in state-of-the-art infrastructure and equipment needed for the development and implementation of nanomaterial-based technologies. Advanced laboratories, imaging facilities, and manufacturing capabilities are essential for the production and testing of nanomaterials, contributing to the growth of personalized medicine applications.

Major market player included in this report are:
Bristol-Myers Squibb Company
Eisai Co., Ltd
Gilead Sciences, Inc
Ipsen Pharma S.A
Abraxis BioScience, Inc
Camurus AB
Johnson & Johnson Services, Inc
Merck & Co., Inc
NanoCarrier Co., Ltd
Novartis AG

Recent Developments in the Market:
 In June 2022, Ligandal Inc., a pioneer in personalised genomic medicine, biomaterials, and artificial intelligence, and Nanotronics, a developer of advanced intelligent inspection systems and adaptive manufacturing hardware has announced a collaboration to commercialise, develop, and provide next-generation technologies for gene therapy, peptide materials, nanomaterials, and biological technology characterization. The firms are going to work to create next-generation nanomaterials and end-to-end capabilities for designing, characterising, synthesising, and supporting diverse therapeutic initiatives, including in rare disease-related applications, haematology, infectious disease, and biodefense.

Global Nanomaterials in Personalized Medicine Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product Type, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

Product Type
Proteins
Monoclonal Antibodies
Nanocrystals
Liposomes
Gold Nanoparticles
Quantum Dots

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.